Differentiated Thyroid Cancer Clinical Trial
Official title:
The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer
The aim of this study is to evaluate the prognostic value of postoperative99mTc-pertechnetate scanning in patients with DTC.
The incidence of thyroid cancer in several affluent countries has markedly increased (1). Although mortality from thyroid cancer has remained relatively low and stable or has steadily declined in these and other countries (2). Therefore, it is still important to identify markers for prognosis prediction and decision-making before radioactive iodine therapy (RIT). Various factors have been reported to be associated with the clinical outcome of RIT. These include preablative stimulated thyroglobulin (ps- Tg), tumor size, extrathyroidal invasiveness, cervical lymph node metastasis and TSH [3,4]. 99mTc pertechnetate is a radiopharmaceutical used for thyroid scintigraphy. The photon energy of 140kev is ideally suited for use with gamma camera. It has short half life of about 6-hoursand no particulate emissions. 99mTc-pertechnetate scintigraphy is a simple, economic and RIT non-interfering technique to evaluate the volume of residual thyroid tissue(RTT). The 99m Tc-pertechnetate uptake of the thyroid bed can be used as a marker of RTT. Although negative uptake doesn't indicate the absence of RTT, it could suggest a small volume. On the other hand, positive uptake can be considered as a large volume of RTT. Several studies have reported that patients with negative 99mTc-pertechnetate uptake have a much higher chance of successful ablation[5, 6]. We hypothesized that negative 99mTc-pertechnetate scintigraphy is a significant predictor for excellent response (ER) to RIT in American Thyroid Association 2015(ATA) low- and intermediate risk DTC patient according to . ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02870569 -
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
|
Phase 2 | |
| Completed |
NCT01876784 -
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
|
Phase 3 | |
| Completed |
NCT04971473 -
Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
|
Phase 3 | |
| Recruiting |
NCT05078853 -
Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma
|
||
| Recruiting |
NCT04964284 -
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03690388 -
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
|
Phase 3 | |
| Recruiting |
NCT02638077 -
Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China
|
N/A | |
| Recruiting |
NCT01700699 -
Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors
|
N/A | |
| Completed |
NCT03176485 -
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
|
N/A | |
| Completed |
NCT03191643 -
PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer
|
N/A | |
| Completed |
NCT02278198 -
Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123
|
Phase 1 | |
| Active, not recruiting |
NCT04447183 -
The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
|
Phase 2 | |
| Active, not recruiting |
NCT01263951 -
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
|
Phase 2 | |
| Active, not recruiting |
NCT04940052 -
Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer
|
Phase 3 | |
| Recruiting |
NCT04880798 -
Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer
|
N/A | |
| Recruiting |
NCT05789667 -
Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer
|
||
| Recruiting |
NCT05660954 -
Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
|
Phase 2 | |
| Completed |
NCT00295763 -
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
|
Phase 3 | |
| Recruiting |
NCT04321954 -
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
|
Phase 2 |